Published in Clin Cancer Res on April 20, 2010
A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev Res (Phila) (2011) 1.70
Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? Nat Rev Urol (2011) 1.20
A candidate molecular biomarker panel for the detection of bladder cancer. Cancer Epidemiol Biomarkers Prev (2012) 1.10
Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests. Mol Diagn Ther (2013) 0.96
External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort. Cancer Epidemiol Biomarkers Prev (2014) 0.87
A new algorithm for integrated analysis of miRNA-mRNA interactions based on individual classification reveals insights into bladder cancer. PLoS One (2013) 0.85
Emerging critical role of molecular testing in diagnostic genitourinary pathology. Arch Pathol Lab Med (2012) 0.85
Molecular diagnostic trends in urological cancer: biomarkers for non-invasive diagnosis. Curr Med Chem (2012) 0.83
Urinary mRNA biomarker panel for the detection of urothelial carcinoma. Oncotarget (2016) 0.83
A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder Cancer. Bladder Cancer (2016) 0.78
Integration Analysis of Three Omics Data Using Penalized Regression Methods: An Application to Bladder Cancer. PLoS Genet (2015) 0.77
Urothelial Bladder Cancer Urinary Biomarkers. EJIFCC (2014) 0.76
A Nomogram Derived by Combination of Demographic and Biomarker Data Improves the Noninvasive Evaluation of Patients at Risk for Bladder Cancer. Cancer Epidemiol Biomarkers Prev (2016) 0.76
Synthesis of a cell penetrating peptide modified superparamagnetic iron oxide and MRI detection of bladder cancer. Oncotarget (2016) 0.75
Bladder cancer: Gene-expression signature in urine indicates aggressive disease. Nat Rev Urol (2010) 0.75
Diagnosis: Gene-expression signature in urine diagnoses aggressive bladder cancer. Nat Rev Clin Oncol (2010) 0.75
MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol (2011) 3.57
Caveolin-1 is essential for liver regeneration. Science (2006) 2.77
Laparoscopic living-donor nephrectomy: analysis of the existing literature. Eur Urol (2010) 2.07
Air cystoscopy is superior to water cystoscopy for the diagnosis of active hematuria. J Urol (2013) 2.06
Molecular lymph node staging in bladder urothelial carcinoma: impact on survival. Eur Urol (2008) 2.04
Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension. Eur Urol (2010) 1.99
Nephrin mutations cause childhood- and adult-onset focal segmental glomerulosclerosis. Kidney Int (2009) 1.88
Cholesterol and fatty acids regulate dynamic caveolin trafficking through the Golgi complex and between the cell surface and lipid bodies. Mol Biol Cell (2005) 1.86
Identification and characterization of associated with lipid droplet protein 1: A novel membrane-associated protein that resides on hepatic lipid droplets. Traffic (2006) 1.82
Laparoscopic kidney transplantation. Eur Urol (2009) 1.68
Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guérin. Eur Urol (2008) 1.65
Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (2008) 1.63
DNA microarray expression profiling of bladder cancer allows identification of noninvasive diagnostic markers. J Urol (2009) 1.59
Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment. BJU Int (2012) 1.58
Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guérin response in patients with T1G3 high-risk bladder tumours. Eur Urol (2011) 1.55
Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guérin therapy. Eur Urol (2007) 1.55
Incompletely penetrant PKD1 alleles mimic the renal manifestations of ARPKD. J Am Soc Nephrol (2010) 1.52
Genetic predisposition to early recurrence in clinically localized prostate cancer. BJU Int (2012) 1.50
Prognostic value of microRNA expression pattern in upper tract urothelial carcinoma. BJU Int (2014) 1.49
The influence of family history on prostate cancer risk: implications for clinical management. BJU Int (2010) 1.48
Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol (2011) 1.47
Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors. Urology (2009) 1.47
Orthotopic kidney transplantation: an alternative surgical technique in selected patients. Eur Urol (2010) 1.45
Can we improve the definition of high-risk, hormone naïve, non-metastatic prostate cancer? BJU Int (2014) 1.44
Can we identify those patients who will benefit from prostate-sparing surgery? Predictive factors for invasive prostatic involvement by transitional cell carcinoma. Can J Urol (2011) 1.44
Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: a GEMCAD study. Cancer Biol Ther (2011) 1.40
Recent advances of natural orifice transluminal endoscopic surgery in urological surgery. Int J Urol (2013) 1.39
High-resolution CT by diffraction-enhanced x-ray imaging: mapping of breast tissue samples and comparison with their histo-pathology. Phys Med Biol (2007) 1.23
TRPC6 mutational analysis in a large cohort of patients with focal segmental glomerulosclerosis. Nephrol Dial Transplant (2009) 1.21
Lymphadenectomy in the surgical management of penile cancer. Eur Urol (2009) 1.19
Phase-contrast X-ray imaging of breast. Acta Radiol (2010) 1.15
Utility of fluorescence in situ hybridization as a non-invasive technique in the diagnosis of upper urinary tract urothelial carcinoma. Eur Urol (2006) 1.14
Prevalence of cysts in seminal tract and abnormal semen parameters in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2008) 1.12
Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer. Mol Cancer Ther (2014) 1.07
Annexin A6-induced alterations in cholesterol transport and caveolin export from the Golgi complex. Traffic (2007) 1.05
Identification of docetaxel resistance genes in castration-resistant prostate cancer. Mol Cancer Ther (2011) 1.04
Clinical value of NPHS2 analysis in early- and adult-onset steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol (2010) 1.03
Toward high-contrast breast CT at low radiation dose. Radiology (2008) 1.02
Conservative surgical therapy for leydig cell tumor. J Urol (2007) 1.02
Multiplex protein signature for the detection of bladder cancer in voided urine samples. J Urol (2013) 1.01
Autosomal recessive Alport's syndrome and benign familial hematuria are collagen type IV diseases. Am J Kidney Dis (2003) 1.00
Using microRNA profiling in urine samples to develop a non-invasive test for bladder cancer. Int J Cancer (2013) 1.00
Coronavirus E protein forms ion channels with functionally and structurally-involved membrane lipids. Virology (2012) 0.99
Primary congenital bladder diverticula in children. Urology (2007) 0.98
Percutaneous nephroscopic management of upper urinary tract transitional cell carcinoma: recurrence and long-term followup. J Urol (2004) 0.98
Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer. Prostate (2012) 0.97
Treatment costs of prostate cancer in the first year after diagnosis: a short-term cost of illness study for France, Germany, Italy, Spain and the UK. BJU Int (2010) 0.97
Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int (2005) 0.97
The organizational and operational boundaries of triple bottom line reporting: a survey. Environ Manage (2008) 0.96
NPHS2 mutations in steroid-resistant nephrotic syndrome: a mutation update and the associated phenotypic spectrum. Hum Mutat (2013) 0.95
Insights on the permeability of wide protein channels: measurement and interpretation of ion selectivity. Integr Biol (Camb) (2010) 0.95
HLA-DQA1 and PLA2R1 polymorphisms and risk of idiopathic membranous nephropathy. Clin J Am Soc Nephrol (2013) 0.95
Genetic testing for X-linked Alport syndrome by direct sequencing of COL4A5 cDNA from hair root RNA samples. Am J Kidney Dis (2007) 0.95
Partially degraded RNA from bladder washing is a suitable sample for studying gene expression profiles in bladder cancer. Eur Urol (2006) 0.94
Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. BJU Int (2008) 0.94
High resolution X chromosome-specific array-CGH detects new CNVs in infertile males. PLoS One (2012) 0.94
Multidetector CT of living renal donors: lessons learned from surgeons. Radiographics (2010) 0.93
Dielectric saturation of water in a membrane protein channel. Phys Chem Chem Phys (2008) 0.93
Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy? World J Urol (2014) 0.92
Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. J Urol (2005) 0.92
Clinical and pathological outcomes of renal cell carcinoma (RCC) in native kidneys of patients with end-stage renal disease: a long-term comparative retrospective study with RCC diagnosed in the general population. World J Urol (2014) 0.92
Electrostatic properties and macroscopic electrodiffusion in OmpF porin and mutants. Bioelectrochemistry (2007) 0.91
Refraction and scattering of X-rays in analyzer-based imaging. J Synchrotron Radiat (2007) 0.91
Spanish Multicenter Normative Studies (NEURONORMA Project): norms for verbal fluency tests. Arch Clin Neuropsychol (2009) 0.91
Spanish Multicenter Normative Studies (NEURONORMA Project): norms for Boston naming test and token test. Arch Clin Neuropsychol (2009) 0.90
Simulation of small-angle x-ray scattering from collagen fibrils and comparison with experimental patterns. Phys Med Biol (2005) 0.90
Spanish Multicenter Normative Studies (NEURONORMA Project): norms for verbal span, visuospatial span, letter and number sequencing, trail making test, and symbol digit modalities test. Arch Clin Neuropsychol (2009) 0.90
The case for conservative management in the treatment of patients with non-muscle-invasive micropapillary bladder carcinoma without carcinoma in situ. Can J Urol (2010) 0.90
DNA variant databases improve test accuracy and phenotype prediction in Alport syndrome. Pediatr Nephrol (2013) 0.89
Spanish multicenter normative studies (Neuronorma project): norms for the abbreviated Barcelona Test. Arch Clin Neuropsychol (2010) 0.89
Utility of a multiprobe fluorescence in situ hybridization assay in the detection of superficial urothelial bladder cancer. Cancer Genet Cytogenet (2007) 0.89